Neogenomics Stock

Neogenomics Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Neogenomics (NEO) as of Aug 6, 2026 is -4.84 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -8.92 % — a change of -45.73% (higher).

Cash Conversion

-4.84 %

YoY

-45.73%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Neogenomics is 2026 -4.84 % . Cash Conversion Rate (OCF/Net Income) of Neogenomics was 2025 -8.92 % . It decreases by -45.73% higher compared to the previous year.
Access this data via the Eulerpool API

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

Cash Conversion Rate (OCF/Net Income) of Neogenomics is -4.84 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Neogenomics changed from -8.92 % to -4.84 %, representing a -45.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Neogenomics since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Neogenomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Neogenomics

All Key Metrics — Neogenomics